Overview
?
John Charles Reader
See more contacts
Scientific Research and Development Services
,
Pharmaceutical and Medicine Manufacturing
,
Professional, Scientific, and Technical Services
,
Biotechnical research, commercial
,
Pharmaceutical preparations
Accounting, Tax Preparation, Bookkeeping, and Payroll Services
,
Advertising, Public Relations, and Related Services
,
Architectural, Engineering, and Related Services
,
Computer Systems Design and Related Services
,
Legal Services
,
Management, Scientific, and Technical Consulting Services
,
Other Professional, Scientific, and Technical Services
,
Specialized Design Services
?
?
Estimated
$57,521
Actual
$2
JUN
?
?
London SETS:SAR
Contacts
Get in Touch with 5 Principals*
-
John Charles ReaderDirector
-
Contact 2?
-
Contact 3?
-
Contact 4?
Dynamic search and list-building capabilities
Real-time trigger alerts
Comprehensive company profiles
Valuable research and technology reports
Financial Statements
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Financial data as of June 30, 2020 (12 month period) in USD
Annual Revenue 2024
$57,521
USD
Actual
1 USD = 0.8206 GBP
All financial statement data is in millions except per share data | Source: Morningstar
| Cash Flow (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net Operating Cash | -$5 | -$4 | -$3 |
| Net Investing Cash | $0 | $ | -$0 |
| Net Financing Cash | $5 | $ | $5 |
| Net Change in Cash | $1 | -$4 | $2 |
| Cash at Beginning of Period | $1 | $5 | $3 |
| Cash at End of Period | $2 | $1 | $5 |
| Capital Expenditure | $ | $ | -$0 |
| Assets (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Assets | |||
| Cash and Cash Equivalents | $2 | $1 | $5 |
| Accounts Receivable | $ | $ | $ |
| Inventories | $ | $ | $ |
| Other Current Assets | $2 | $1 | $1 |
| Asset Summary | |||
| Total Current Assets | $3 | $2 | $6 |
| Tangible Fixed Assets | $ | $0 | $0 |
| Intangible Assets | $ | $ | $ |
| Total Assets | $3 | $2 | $5 |
| Liabilities (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Liabilities | |||
| Accounts Payable | $1 | $1 | $0 |
| Short-Term Debt | $ | $ | $ |
| Other Current Liabilities | $0 | $0 | $0 |
| Liability Summary | |||
| Total Current Liabilities | $1 | $1 | $1 |
| Long-Term Debt | $ | $ | $ |
| Other Long-Term Liabilities | $ | $ | $ |
| Total Liabilities | $1 | $1 | $1 |
| Stakeholder's Equity (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Equity | |||
| Common Stock | $2 | $1 | $1 |
| Retained Earnings | -$30 | -$26 | -$22 |
| Equity Summary | |||
| Total Equity | $3 | $1 | $5 |
| Shares Outstanding | 107,945,783 | 68,069,416 | 68,069,416 |